Trial · NCT02948075
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NCT02948075, Phase 2, Completed, NewVac LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy. Trials, record NCT02948075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02948075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
- NCT number
- NCT02948075
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 31 participants, actual
- Lead sponsor
- NewVac LLC
- Conditions
- Ovarian Cancer
- Interventions
- Quisinostat, Paclitaxel, Carboplatin
- First posted
- 2016-10-28
- Last updated
- 2018-06-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate | up to week 54 | assessment of the objective response rate ORR (complete response (CR) plus partial response (PR)) according to RECIST 1.1 criteria |
| Secondary | Progression-free survival (PFS) | up to week 54 | |
| Secondary | Time to progression (TTP) | up to week 54 | |
| Secondary | Overall survival (OS) | up to week 54 | |
| Secondary | The percentage of patients in which the TTP1 on the first line chemotherapy with Carboplatin and Paclitaxel is shorter than TTP2 for the patients on second line chemotherapy with Carboplatin, Paclitaxel and Quisinostat | up to week 54 | |
| Secondary | Determination of E-Cadherin, ERCC1 and BRCA1 expression as potential predictive biomarkers for Quisinostat induced sensitivity to chemotherapy | up to week 54 | the measurement will be conducted using tumor tissue samples |
| Secondary | Incidence and severity of adverse events (AEs), including serious AEs (SAEs), graded according to the National Cancer Institute (NCI) CTCAE version 4.03 | up to week 54 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02948075
GET https://conductscience.org/api/trials/v1/NCT02948075/registered